Name
EstPharma OÜ
Registry code
14915921
VAT number
EE102242135
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
19.02.2020 (4)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
47731 - Dispensing chemist in specialised stores
4 359 356 €
-143 437 €
-3%
-
-288 152 €
17
Submitted
No tax arrears
50%
-19%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Omanikukonto: Merilin Nurk-Bonde 05.02.1985 (39) | 100% - 2 500.00 EUR | Board member | Direct ownership | Founder |
| 2020 30.06.2021 | 2021 30.06.2022 | 2022 30.06.2023 | 2023 30.06.2024 | |
|---|---|---|---|---|
| Total Revenue | 2 668 745 € | 3 020 027 € | 3 378 784 € | 4 359 356 € |
| Net profit (loss) for the period | -132 625 € | 83 937 € | -98 527 € | -143 437 € |
| Profit Margin | -5% | 3% | -3% | -3% |
| Current Assets | 661 121 € | 474 132 € | 677 372 € | 739 828 € |
| Fixed Assets | - | 1 772 € | 1 227 € | 682 € |
| Total Assets | 661 121 € | 475 904 € | 678 599 € | 740 510 € |
| Current Liabilities | 791 246 € | 522 092 € | 823 314 € | 1 028 662 € |
| Non Current Liabilities | - | - | - | - |
| Total Liabilities | - | - | - | - |
| Share Capital | - | - | - | - |
| Equity | -130 125 € | -46 188 € | -144 715 € | -288 152 € |
| Employees | 17 | 14 | 17 | 17 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 1 293 960.26 € | 78 291.04 € | 67 714.73 € | 26 |
| 2023 Q4 | 1 193 162.9 € | 77 783.09 € | 68 965.52 € | 25 |
| 2023 Q3 | 1 107 076.16 € | 77 608.46 € | 71 459.01 € | 23 |
| 2023 Q2 | 1 184 114.68 € | 69 617.82 € | 63 289.72 € | 24 |
| 2023 Q1 | 1 151 555.04 € | 68 432.57 € | 63 008.87 € | 25 |
| 2022 Q4 | 1 069 044.21 € | 69 725 € | 63 541.53 € | 24 |
| 2022 Q3 | 790 953.85 € | 52 181.93 € | 49 478.28 € | 26 |
| 2022 Q2 | 799 018.52 € | 50 954.34 € | 40 858.51 € | 20 |
| 2022 Q1 | 820 536.11 € | 52 883.47 € | 43 461.47 € | 18 |
| 2021 Q4 | 854 842.75 € | 54 341.99 € | 42 535.97 € | 18 |
| 2021 Q3 | 710 427.5 € | 54 352.86 € | 44 628.19 € | 17 |
| 2021 Q2 | 792 282.38 € | 48 195.45 € | 41 147.68 € | 18 |
| 2021 Q1 | 922 395.98 € | 80 818.91 € | 57 865.36 € | 18 |
| 2020 Q4 | 1 025 953.3 € | 50 212.19 € | 46 584.61 € | 24 |
| 2020 Q3 | 883 425.08 € | 48 512.32 € | 43 615.47 € | 22 |
| 2020 Q2 | 581 237.76 € | 21 476.84 € | 18 217.73 € | 23 |
| 2020 Q1 | - | - | - | 25 |
